Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda in neoadjuvant esophageal and gastric cancers
NCT03064490Phase 2Completed
- Sponsor
- Duke University
- Start
- Oct 2017
- Primary completion
- Feb 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in esophageal adenocarcinoma (EAC), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Duke University. Started Oct 2017; status: completed.
02
Drugs
03
Conditions
esophageal adenocarcinoma (EAC)gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03064490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03064490.